As CDK4-targeted therapy, CDK4/6 inhibitors (e.g., abemaciclib, palbociclib, ribociclib) are currently widely used for the treatment of breast cancer, and their therapeutic value in this disease context has attracted significant attention (30–33). The gene discussed is CDK4; the disease is breast cancer.